Table 3.
Response to eribulin according to RECIST 1.1 criteria, with a dichotomization on sensitivity to the latest previous microtubule-targeting therapy
| Whole population (n=206) | Responder (n=108) | Non-responder (n=98) | p-value | |
|---|---|---|---|---|
| Response rate | ||||
| Complete response | 2 (1.1) | 2 (2.0) | 0 | 0.086 |
| Partial response | 30 (16.7) | 19 (19.4) | 11 (13.4) | |
| Stable disease | 64 (35.6) | 39 (39.8) | 25 (30.5) | |
| Progressive disease | 84 (46.7) | 38 (38.8) | 46 (56.1) | |
| Objective response rate | 32 (17.8) | 21 (21.4) | 11 (13.4) | 0.228 |
| Disease control rate | 96 (53.3) | 60 (61.2) | 36 (43.9) | 0.020 |
Values are presented as number (%). RECIST, Response Evaluation Criteria in Solid Tumor.